Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
Research describes new way of shrinking ovarian cancer tumors, improving drug delivery

Research describes new way of shrinking ovarian cancer tumors, improving drug delivery

New research published in the February 2015 issue of The FASEB Journal, may eventually help improve the five-year survival rate of ovarian cancer patients by describing a new way of shrinking ovarian cancer tumors while also simultaneously improving drug delivery. [More]
Project Spark to advance neuroprotective drug for schizophrenia-associated cognitive impairment

Project Spark to advance neuroprotective drug for schizophrenia-associated cognitive impairment

A public-private consortium led by the biotech Iproteos -based at Parc CientĂ­fic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders. [More]
Micromotor fueled by stomach acid effectively delivers gold nanoparticles

Micromotor fueled by stomach acid effectively delivers gold nanoparticles

Researchers at the University of California, San Diego have shown that a micromotor fueled by stomach acid can take a bubble-powered ride inside a mouse. These tiny motors, each about one-fifth the width of a human hair, may someday offer a safer and more efficient way to deliver drugs or diagnose tumors. [More]
Nuvo Research announces topline results from WF10 Phase 2 allergic rhinitis clinical trial

Nuvo Research announces topline results from WF10 Phase 2 allergic rhinitis clinical trial

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced the results of its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial conducted in Germany to compare the safety and efficacy of WF10 and its main constituents (sodium chlorite and sodium chlorate) with saline in patients with refractory allergic rhinitis and to compare the safety and efficacy of WF10 and its main constituents. [More]
Researchers create customized soap bubbles that promote drug and vaccine delivery

Researchers create customized soap bubbles that promote drug and vaccine delivery

When University of Maryland Professors Philip DeShong and Daniel Stein began tagging soap bubbles with biomolecules, they had no idea this technology would one day be poised to change the way drugs and vaccines fight against bacteria, viruses and cancer. [More]
Attaching Epirubicin drug to nanodiamonds eliminates chemoresistant cancer stem cells

Attaching Epirubicin drug to nanodiamonds eliminates chemoresistant cancer stem cells

A study led by the National University of Singapore found that attaching chemotherapy drug Epirubicin to nanodiamonds effectively eliminates chemoresistant cancer stem cells. The findings were first published online in ACS Nano, the official journal of the American Chemical Society, in December 2014. [More]
Echo Therapeutics re-establishes operational and strategic partnership with MTIA

Echo Therapeutics re-establishes operational and strategic partnership with MTIA

Echo Therapeutics, Inc., a medical device company focused on skin permeation, continuous glucose monitoring, and associated technologies, announced today that it has re-established its operational and strategic partnership with Medical Technologies Innovation Asia, Ltd., Hong Kong, and has initiated the technology transfer process. [More]
Cohera Medical, B. Braun sign sales and distribution agreement for TissuGlu Surgical Adhesive

Cohera Medical, B. Braun sign sales and distribution agreement for TissuGlu Surgical Adhesive

Cohera Medical, Inc., a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that it has entered into an exclusive sales and marketing distribution agreement with B. Braun for its TissuGlu Surgical Adhesive in Germany, Spain and Portugal. [More]
Celator Pharmaceuticals' CPX-351 receives FDA Fast Track designation for secondary AML treatment

Celator Pharmaceuticals' CPX-351 receives FDA Fast Track designation for secondary AML treatment

Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that the U.S. Food and Drug Administration granted Fast Track designation for CPX-351 (cytarabine:daunorubicin) for the treatment of elderly patients with secondary Acute Myeloid Leukemia (AML). [More]
New colloidal gold test strip demonstrates great potential for early detection of heart attack

New colloidal gold test strip demonstrates great potential for early detection of heart attack

NYU Polytechnic School of Engineering professors have been collaborating with researchers from Peking University on a new test strip that is demonstrating great potential for the early detection of certain heart attacks. [More]
BioLight invests in newly-formed ophthalmic company

BioLight invests in newly-formed ophthalmic company

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced its investment in a newly-formed ophthalmic company that has licensed-in a world-wide drug-delivery platform from the Hebrew University, Israel, that has the potential to enable more efficient and safer delivery of eye drops. [More]
MGB Biopharma provides update on business performance for 2014

MGB Biopharma provides update on business performance for 2014

MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives, provides an update on its business performance for 2014. MGB Biopharma is developing a pipeline of novel antimicrobials that puts it at the forefront of addressing the major global problem of antimicrobial resistance. [More]
FDA approves RYTARY for Parkinson's disease treatment

FDA approves RYTARY for Parkinson's disease treatment

Impax Pharmaceuticals, a division of Impax Laboratories, Inc., today announced that the U.S. Food and Drug Administration approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication. [More]
BD Medical announces FDA clearance of BD Intelliport Medication Management System

BD Medical announces FDA clearance of BD Intelliport Medication Management System

BD Medical, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, today announced that the U.S. Food and Drug Administration has cleared the BD Intelliport Medication Management System, the first-of-its-kind medication management solution for manual IV bolus injections. [More]
Novel drug delivery technique uses graphene to deliver two anticancer drugs sequentially to cancer cells

Novel drug delivery technique uses graphene to deliver two anticancer drugs sequentially to cancer cells

An international team of researchers has developed a drug delivery technique that utilizes graphene strips as "flying carpets" to deliver two anticancer drugs sequentially to cancer cells, with each drug targeting the distinct part of the cell where it will be most effective. The technique was found to perform better than either drug in isolation when tested in a mouse model targeting a human lung cancer tumor. [More]
EnGeneIC closes oversubscribed Series B financing

EnGeneIC closes oversubscribed Series B financing

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing. [More]
CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer. [More]
Nuvo Research completes WF10 Phase 2 trial in patients with refractory allergic rhinitis

Nuvo Research completes WF10 Phase 2 trial in patients with refractory allergic rhinitis

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of immunology and topical products, today announced that 179 patients have completed its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial to investigate the safety and efficacy of WF10 in patients with refractory allergic rhinitis. [More]
Most people with asthma or severe allergies do not use medical devices correctly, study finds

Most people with asthma or severe allergies do not use medical devices correctly, study finds

For people with asthma or severe allergies, medical devices like inhalers and epinephrine autoinjectors, such as EpiPen, can be lifesaving. [More]
Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

Preclinical study strongly supports NT-113 as potential new treatment for glioblastoma multiforme

NewGen Therapeutics, Inc. today announced the publication of preclinical research strongly supporting NT-113, the company's novel irreversible pan-erbB inhibitor (EGFR, HER2 and HER4), as a potential new treatment for glioblastoma multiforme (GBM), the most common and most aggressive malignant primary brain tumor in adults. [More]